NCT06636071进行中（未招募）3 期
An Open-label Phase 3 Study of Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta Type I, III, or IV
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
- 试验地点
- 3
- 主要终点
- Annualized Rate of All Radiographically-Confirmed Fractures, Including Morphometric Vertebral Fractures During the Treatment Period
研究概览
简要总结
The primary objective of the study is to evaluate the effect of setrusumab on reduction in fracture rate, including morphometric vertebral fractures.
详细描述
This study will be conducted in Japan only and consists of a screening period, an open-label treatment period, and an open-label extension period. Participants will receive setrusumab for up to 24 months during the open-label Treatment Period followed by continued setrusumab treatment during the open-label Extension Period. All participants will receive setrusumab until it becomes commercially available in Japan, consent is withdrawn, or the study is otherwise discontinued.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 6 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of OI Type I, III, or IV confirmed by identification of genetic mutation in COL1A1 or COL1A2
- •History of ≥ 1 fracture in the past 12 months, ≥ 2 fractures in the past 24 months, or ≥ 1 femur, tibia, or humerus fracture in the past 24 months
- •Any prior exposure to, or currently receiving, IV-bisphosphonate therapy for treatment of OI
- •Serum 25-hydroxyvitamin D level ≥ 20 ng/mL at the Screening visit. If 25- hydroxyvitamin D levels are below 20 ng/mL, the subject may be rescreened after a minimum of 14 days of vitamin D supplementation as directed by the Investigator
排除标准
- •History of skeletal malignancies or bone metastases at any time
- •History of neural foraminal stenosis (except if due to scoliosis)
- •Clinical manifestations of Chiari malformation or basilar invagination. Presence of any other neurologic disease that has been clinically unstable within past 2 years requires review by the Medical Monitor.
- •History of or current uncontrolled concomitant diseases that may impact bone metabolism, such as hypo/hyperparathyroidism, abnormal thyroid function, nephrotic syndrome, or Stage IV/V renal disease
- •Any skeletal condition (other than OI) leading to bone deformity and/or increased risk of fractures, such as rickets, osteopetrosis, idiopathic juvenile osteoporosis, or skeletal dysplasia
- •History of known cardiovascular disease such as coronary artery anomaly, Kawasaki disease, myocarditis, cardiomyopathy, myocardial infarction, stroke, or thromboembolic disease. Individuals with other congenital or acquired cardiovascular disease necessitating an echocardiogram require Medical Monitor review. Investigators should consider whether the potential benefits of treatment outweigh the potential risks in patients with cardiovascular risk factors such as confirmed arterial hypertension.
- •Hypocalcemia, defined as serum calcium levels below the age-adjusted normal limit reference ranges after a recommended ≥ 4 hour fast, at Screening
- •Estimated glomerular filtration rate ≤ 35 mL/min/1.73 m2 at Screening
- •Prior treatment with growth hormone, denosumab, anti-sclerostin antibody, or other anabolic or anti-resorptive medications impacting the bone (other than bisphosphonates) at any time
- •History of external radiation therapy
- •Known hypersensitivity to setrusumab or its excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects
- •Presence or history of any condition that, in the view of the Investigator, would interfere with participation, pose undue risk, or would confound interpretation of results
- •Use of any investigational product or investigational medical device within 4 weeks or 5 half-lives (whichever is longer) of investigational drug prior to Screening, or during the study (per discretion of the Investigator in consultation with the Medical Monitor)
- •Concurrent participation in another clinical study without prior approval from the study Medical Monitor
- •Pregnant or nursing
研究组 & 干预措施
Setrusumab
Experimental
干预措施: setrusumab (Biological)
结局指标
主要结局
Annualized Rate of All Radiographically-Confirmed Fractures, Including Morphometric Vertebral Fractures During the Treatment Period
时间窗: Up to Month 24
次要结局
- Serum Setrusumab Concentration Over Time(Up to Month 24)
- Annualized Rate of Radiographically-Confirmed Fractures, Excluding Morphometric Vertebral Fractures, but Including Fractures of the Fingers, Toes, Face, and Skull During the Treatment Period(Up to Month 24)
- Annualized Rate of All Radiographically-Confirmed Fractures, Excluding Morphometric Vertebral Fractures and Fractures of the Fingers, Toes, Face, and Skull During the Treatment Period(Up to Month 24)
- Change from Baseline in Dual-Energy X-Ray Absorptiometry (DXA) Bone Mineral Density (BMD) Z-Score at the Lumbar Spine During the Treatment Period(Baseline, Up to Month 24)
- Percent Change from Baseline in DXA BMD at the Lumbar Spine During the Treatment Period(Baseline, Up to Month 24)
- Proportion of Participants Experiencing New Radiographically-Confirmed Fractures, Including Morphometric Vertebral Fractures, at the Primary Analysis(Up to Month 24)
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs), Frequency, Severity and Relationship to Treatment(Up to Month 24)
- Incidence of Binding and Neutralizing Anti-Setrusumab Antibodies Over Time(Baseline, Up to Month 24)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
2 期
Setrusumab vs Placebo for Osteogenesis ImperfectaOsteogenesis ImperfectaNCT05125809Ultragenyx Pharmaceutical Inc183
已完成
3 期
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of AgePsoriasisNCT02698475Janssen Research & Development, LLC44
进行中（未招募）
3 期
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis ImperfectaOsteogenesis ImperfectaNCT05768854Ultragenyx Pharmaceutical Inc69
进行中（未招募）
3 期
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome ParticipantsMyelodysplastic SyndromesNCT06045689Bristol-Myers Squibb106
撤回
3 期
Study of Epratuzumab in Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT00382837UCB Pharma